Objective: To examine the temporal relationship between the anti-discrimination rules of the Affordable Care Act, which took full effect in 2017, and the incidence of commercial claims for gender-affirming care, as well as cost sharing for these services.

Methods: We used a previously described algorithm to define a cohort of gender-diverse adults in the MarketScan Commercial Claims and Encounters Database. Claims for gender-affirming medical and surgical care were identified using International Classification of Diseases and Current Procedural Terminology codes plus pharmacy data; the annual incidence of surgical claims was calculated. Interrupted time series analyses were used to evaluate the temporal relationship between claims and anti-discrimination legislation. Claims data were also used to evaluate the patient contribution towards services.

Results: There were 70,733 gender-diverse adults included in the study and 36,702 (51.9%) of them filed claims for gender-affirming care. The incidence of persons with claims for gender-affirming surgery increased from 0.002% in 2009 to 0.012% in 2021. Interrupted time series analyses demonstrated a greater year-to-year increase in claims after anti-discrimination policy influences took effect. This change was greatest for transmasculine chest procedures. The median lifetime net payment for gender-affirming surgery was $12,429.10 and cost sharing was $1019.20 (8.6%).

Conclusion: Commercial claims for gender-affirming surgery increased temporally with respect to implementation of anti-discrimination legislation and cost-sharing was reasonably low. However, many gender-diverse persons did not have claims for gender-affirming care, which may indicate continued out-of-pocket payment for these services.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2024.05.025DOI Listing

Publication Analysis

Top Keywords

claims gender-affirming
24
gender-affirming care
16
anti-discrimination legislation
12
claims
12
commercial claims
12
gender-affirming surgery
12
gender-affirming
8
temporal relationship
8
cost sharing
8
gender-diverse adults
8

Similar Publications

AusPATH: Activism influencing health policy.

Australas Psychiatry

January 2025

Senior Clinical Lecturer, Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA, Australia.

Objective: To consider the role of AusPATH and its position statements on health policy in Australia.

Conclusions: As a consequence of a membership policy which admits members with lived experience as health experts, AusPATH functions as an activist organisation whilst claiming to be a professional association. There is no accreditation or endorsement underpinning AusPATH's influence on health policy in Australia.

View Article and Find Full Text PDF

Five-Year Fracture Rate for Transgender and Gender Diverse Patients on Gender-Affirming Hormone Therapy.

J Am Acad Orthop Surg

December 2024

From the University of Michigan Medical School, Ann Arbor, MI (Jacobson), the Department of Physical Medicine and Rehabilitation (Whitney), Department of Orthopedic Surgery (Mamdouhi and Ahn), Consulting for Statistics, Computing and Analytics Research (Janney), and Department of Family Medicine (Blaszczak), University of Michigan, Ann Arbor, MI, and the Department of Orthopaedics, Emory University and Grady Health, Atlanta, GA (Ahn).

Introduction: Gender-affirming hormone therapy (GAHT) is a cornerstone of gender-affirming care for transgender and gender diverse (TGD) patients, with a direct biological role on bone metabolism. However, a paucity of data describes how GAHT influences fracture rate over time. The study's primary objective was to describe the 5-year all-cause fracture incidence rate (IR) among TGD patients initiating estrogen-based GAHT (E-GAHT) or testosterone-based GAHT (T-GAHT), compared with TGD patients not using GAHT (non-GAHT).

View Article and Find Full Text PDF

Gender-affirming medical treatment for adolescents: a critical reflection on "effective" treatment outcomes.

BMC Med Ethics

December 2024

Center of Expertise on Gender Dysphoria (CEGD), Amsterdam UMC, Vrije Universiteit, De Boelelaan 1118, Amsterdam, 1081 HZ, The Netherlands.

Background: The scrutiny surrounding gender-affirming medical treatment (GAMT) for youth has increased, particularly concerning the limited evidence on long-term treatment outcomes. The Standards of Care 8 by the World Professional Association for Transgender Health addresses this by outlining research evidence suggesting "effective" outcomes of GAMT for adolescents. However, claims concerning what are considered "effective" outcomes of GAMT for adolescents remain implicit, requiring further reflection.

View Article and Find Full Text PDF

In the U.S. Court of Appeals for the First Circuit adopted The World Professional Association of Transgender Health Standards of Care (WPATH SOC) as medical consensus on gender affirming care and held that Michelle Kosilek could access gender affirming care but that she did not meet the criteria for gender affirming surgery.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the social context surrounding the access and administration of gender-affirming hormonal therapy (GAHT) for trans individuals in Russia, highlighting factors that influence these practices.
  • Interviews with 20 trans individuals and 6 endocrinologists reveal that while more endocrinologists are becoming knowledgeable about GAHT, many trans people still self-medicate due to barriers like cost, age, and lack of diagnosis.
  • The research concludes that current political and medical frameworks in Russia make it challenging to adopt a more progressive model of GAHT provision, as the diagnosis of "transsexualism" remains essential for safeguarding both healthcare providers and patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!